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Abstract
Malignancies of the thymus are a rare entity and are often without local symp-
toms. However, paraneoplastic syndromes can give symptoms varying from very 
mild to life-threatening. The diagnostic workup and management of these tumors 
warrant a multidisciplinary approach. Treatment choice is mainly decided upon 
by pathological World Health Organization (WHO) subtype and clinical staging. 
In contrast to historical belief, biopsy could be considered when indicated. For 
resectable tumors, surgical approach is advised, with adjuvant radiotherapy for 
Masaoka-Koga stage III tumors. Whether Masaoka-Koga stage II tumors should 
be treated with radiotherapy is controversial given different outcomes in multiple 
studies. In Masaoka-Koga stage III, combinations with induction chemotherapy are 
the standard. A surgical approach should be considered even in stage IVa disease. 
If distant metastases are present, the patient can be treated with systemic chemo-
therapy. Despite many phase II studies having been published, there is no random-
ized controlled phase III data regarding optimal treatment available. In addition 
to chemotherapy, sunitinib and octreotide have been described to be effective. 
Immunotherapy is seen as Pandora’s box given the possibility of immune-related 
side effects in this immunological organ. All known data regarding immunotherapy 
will be discussed.
Keywords: thymoma, thymic carcinoma, autoimmune paraneoplastic syndromes, 
surgery, radiation, chemotherapy, immunotherapy, targeted therapy
1. Introduction
Malignancies of the thymus are rare accounting for <1% of all adult neoplasms. 
Thymoma and thymus carcinoma account for 20% of tumors in the anterior medi-
astinum and are therefore the most commonly found malignancy in that specific 
location.
There are several groups of thymic tumors to distinguish thymic epithelial 
tumors, germ cell tumors, lymphoid and hematological malignancies, and mesen-
chymal tumors. It is known that they derive from or differentiate toward thymic 
cellular components, but the etiology of thymic neoplasms is largely unknown [1].
This chapter is about the epithelial tumors thymoma and thymic carcinoma 
(which include the neuroendocrine tumors). These tumors are histologically 
characterized by thymic stroma and lymphocytes. Thymomas usually exhibit a slow 
growth pattern, but they do have malignant potential and show a propensity for 
local invasion and intrathoracic recurrence. Extrathoracic metastases of thymomas 
are quite rare [2]. Thymic carcinomas are more aggressive, with invasion in the sur-
rounding mediastinal structures. Extrathoracic metastases occur in <7% of  
patients [3]. Although thymomas and thymic carcinomas arise mostly in the anterior 
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mediastinum, they can also be found in other mediastinal compartments, as well as 
in the neck, lung, pleura, and thyroid, due to ectopic thymic tissue [1, 4, 5].
Approximately 1000 new cases are diagnosed per year in Europe [6]. Patients 
are usually between 20 and 70 years of age, with a peak in 30–40 years for those 
with myasthenia gravis and 60–70 years for those without myasthenia gravis. 
Incidence is similar in men and women [3, 7]. There are no known risk factors [3, 7],  
although clusters of thymoma are described in patients with multiple endocrine 
neoplasia type 1 (MEN1) syndrome [8] and an association between the Epstein–
Barr virus and myasthenia gravis in thymoma patients has been suggested [9].
2. WHO histological classification
Numerous classifications for thymic neoplasms, based on different histologi-
cal and clinical criteria, have been proposed in the past. For universal agreement 
purposes, the International Committee of the World Health Organization (WHO) 
developed a classification system that distinguishes five histological subtypes of 
thymomas that differ in both morphological and clinical presentation and which 
correlate with invasion [1]. The WHO classification is increasingly more malignant 
from A to B3. Thymomas are composed of a mixture of neoplastic epithelial cells 
and normal T lymphocytes and exhibit a resemblance to the normal thymic archi-
tecture, which cannot be found in other organs. In contrast, thymic carcinoma (in 
the past considered as a thymoma type C) is similar to carcinomas found outside the 
thymus. Although most thymomas have an excellent prognosis, they can be locally 
invasive and are (although rarely) able to spread to lymph nodes or extrathoracic 
sites, so the term “benign” should be avoided.
Type A thymoma is composed of spindle cells and a few to no lymphocytes. 
About 24% of the type A thymomas are found in patients suffering from myasthe-
nia gravis, and pure red cell aplasia may occur. Eighty percent of type A thymomas 
are Masaoka-Koga stage I on presentation (for explanation on the Masaoka-Koga 
staging system, see paragraph on staging). Stage IV is rare in this histological 
subtype [1, 3]. The prognosis of type A thymoma is excellent with 5- and 10-year 
survival rates close to 100% [10].
Type AB thymoma is composed of a mixture of lymphocyte-poor type A 
thymoma and more lymphocyte-rich type B. Approximately 14% of type AB thy-
momas are associated with the development of myasthenia gravis. Paraneoplastic 
pure red cell aplasia has also been also reported. Seventy-two percent is Masaoka-
Koga stage I at presentation, 22% stage II, and 6% stage III. As in WHO type A 
disease, stage IV is rare [1]. Overall 5- and 10-year survival is reported 80–100% 
for stages I and II.
Type B1 thymoma is composed of thymic epithelial cells which are practically 
indistinguishable from the normal thymus cortex and medulla. A prominent popu-
lation of immature lymphocytes is present. Like the other types, type B1 thymoma 
is associated with myasthenia gravis, but additionally hypogammaglobulinemia and 
pure red cell aplasia have been reported. Invasion in adjacent organs occurs in 12% 
of patients [11]. Complete surgical resection is possible in 94% of the cases with a 
recurrence rate of 10%. Ten-year survival rate is >90% [10].
Type B2 thymomas are usually at a more advanced stage. They are predomi-
nantly composed of large, polygonal tumor cells in the background of a large 
population of immature T lymphocytes. The most frequent manifestations (up to 
80%) are symptoms arising from myasthenia gravis. Pure red cell aplasia, hypo-
gammaglobulinemia, and other paraneoplastic autoimmune diseases have been 
described. Up to 53% are stage Masaoka-Koga I or III at presentation, and 8.2% is 
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stage IV. In 5–15% of cases, they are non-resectable, and recurrence rates are 9% 
after complete resection [10, 12]. Reported 10-year survival rates are between 50 
and 100% [1].
Type B3 thymomas are almost always invasive and unresectable at presentation. 
Like the other types of thymomas, the most frequent association is myasthenia 
gravis. Pure red cell aplasia and hypogammaglobinemia are rare. The majority of 
patients are Masaoka-Koga stage II or III at presentation, and stage IV occurs in 
20%. Ten-year survival rates range between 50 and 70% [10, 12, 13].
Thymic carcinomas are atypical, invasive epithelial tumors that show resem-
blance to carcinomas outside the thymus and show a lot of differentiation. 
Squamous cell carcinomas and undifferentiated carcinomas are the most common 
subtypes. They are composed of polygonal or round epithelial cells with mild 
atypia. Invasion of adjacent structures has been reported to occur in 83% of cases. 
In contrast to thymomas, paraneoplastic syndromes are very rare. Thymic carcino-
mas have the worst survival rate of the thymic malignancies with only 35% 5-year 
survival [1, 10, 14].
3. Clinical presentation
Patients with a thymus malignancy can present themselves with complaints due 
to local compression/invasion or due to a paraneoplastic autoimmune phenomenon, 
but ~40% of the thymic neoplasms are asymptomatic incidental findings.
Local symptoms are related to the site and size of tumor and compression or 
invasion on the surrounding tissue. Patients can present themselves with symptoms 
as chest pain, cough, dysphagia, or stridor. A superior vena cava syndrome can 
cause swelling of the face and arms and dyspnea. Dyspnea can also be the result of 
unilateral or bilateral phrenic nerve palsy and pleural or pericardial involvement. 
The latter can also elicit tachycardia [3]. Systemic symptoms such as fever or weight 
loss are possible.
3.1 Paraneoplastic autoimmune syndromes
About 40–50% of thymomas are associated with a variety of paraneoplastic 
autoimmune syndromes, and over 30 associations have been described [1, 15, 16] 
(Table 1). Up to 25% deaths in thymoma are due to the complications of autoim-
mune syndromes.
The most common paraneoplastic syndrome is myasthenia gravis, followed by 
pure red cell aplasia and hypogammaglobinemia (Good syndrome).
Ten to twenty percent of patients with myasthenia gravis have a thymoma, and 
30–50% of patients with thymoma have myasthenia gravis. It is a neuromuscular 
disease that leads to varying degrees of muscle weakness. It is caused by autoanti-
bodies that interfere with the acetylcholine receptors in the neuromuscular junction 
of the voluntary muscles, but the exact mechanism how has yet to be discovered. 
Systemic symptoms consist of fatigue and general muscle weakness leading to 
troubles with walking. Myasthenia gravis can antedate the diagnosis of thymoma, 
be diagnosed concurrently, or occur after thymectomy, with or without recurrence 
of thymoma [15–17].
Pure red cell aplasia is a profound non-regenerative anemia, characterized by a 
severe reduction in reticulocytes and absence of erythrocyte precursors in the bone 
marrow. Five to fifteen percent of patients with thymoma have pure red cell aplasia 
[16]. It is more common in older women. Remission following surgical excision of 
the thymoma is uncommon [18].
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Patients suffering from hypogammaglobulinemia (or Good syndrome) suffer 
from recurrent episodes of diarrhea, pulmonary infections, urinary tract infections, 
and several other bacterial and viral infections. Five percent of patients with Good 
syndrome have a thymoma, and 10% of patients with a thymoma have hyper-
gammaglobulinemia. Thymectomy does not normalize immunoglobulin levels. 
Treatment consists of administration of intravenous immunoglobulin [16, 19].
Thymoma-associated multiorgan autoimmunity (TAMA) is a severe and often 
fatal graft-versus-host-like disease that requires special mention. Symptoms 
are T-cell mediated and cause skin disruptions, liver failure, and diarrhea [3]. 
Immunoglobulin and methylprednisolone have been described as treatment [20].
4. Diagnostics
4.1 Imaging
Thymic epithelial tumors arise in the anterior mediastinum and are most com-
monly located between the sternum, the great vessels, and the pericardium. All 
anterior mediastinal masses should be assessed with a chest computed tomography 
(CT) with IV contrast [21]. Chest CT can usually show if a thymic tumor is well 
circumscribed and if invasion in mediastinal fat, the surrounding vessels, or the 
adjacent lung is present. It can also show the presence of pericardial and/or pleural 
seeding [16]. Magnetic resonance imaging (MRI) can be used to assess involve-
ment of surrounding tissues [22] and can also be useful to differentiate between 
Neuromuscular diseases Myasthenia gravis
Neuromyotonia
Rippling muscle disease
Polymyositis/dermatomyositis
Encephalitis
Intestinal pseudo-obstruction
Hematologic autoimmune diseases Anemia
Pure red cell anemia
Pernicious anemia
Hemolytic anemia
Aplastic anemia
Other isolated cytopenia
Immunodeficiencies
Hypogammaglobinemia/Good syndrome
T-cell deficiencies
Dermatologic diseases Pemphigus
Lichen planus
Alopecia areata
Endocrine disorders Addison’s disease
Cushing’s disease
Graves’ disease
Renal and hepatic disease Glomerulonephritis
Autoimmune hepatitis
Systemic autoimmune diseases SLE
Sjogren’s disease
Systemic sclerosis
Thymoma-associated multiorgan autoimmunity (TAMA)
Table 1. 
Examples of autoimmune syndromes associated with thymoma.
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thymoma and thymic cysts that demonstrate increased CT attenuation due to 
hemorrhage or high mucinous content [16]. It can also be considered in patients that 
cannot tolerate radiocontrast administration.
Thymomas are usually encapsulated, homogenous, and round or oval struc-
tures with smooth contours. A cystic component is common. They can range from 
microscopic size to >30 cm in diameter. Type B thymomas and thymic carcinomas 
can show calcifications [22]. Thymic carcinomas tend to have irregular borders and 
necrotic areas and are usually much larger than thymomas. Pleural seeding is seen 
in both invasive thymoma and thymic carcinoma [23].
Positron-emission tomography (PET) can be useful in the case of thymic car-
cinoma. Thymic carcinomas have a higher fludeoxyglucose (FDG-18) PET uptake 
than thymomas. Using a standardized uptake value (SUV) cutoff point of 5.0, 
thymic carcinoma can be distinguished from thymomas with a sensitivity of 84.6% 
and a specificity of 92.3%. PET can also be useful for diagnosis of extra thoracic 
metastases in thymus carcinoma [24].
4.2 Biopsy
When a thymic tumor is considered likely and microscopical complete resection 
is considered possible, pathological evaluation should be done following surgery. 
Most thymomas can reliably be identified on the clinical presentation and imaging 
without the need for a biopsy. Histological classification may be difficult when 
there is a limited amount of tissue, and invasion in the surrounding tissue cannot be 
identified on biopsy alone. So even when the diagnosis is uncertain based on clinical 
presentation and imaging alone, complete surgical resection is advised for both 
diagnostic and treatment purposes [21].
Historically, it is thought that biopsy can cause pleural seeding. This is the main 
reason it is recommended to avoid a biopsy when resectable thymoma is suspected 
[21, 25]. However, there are no known exact data available to describe the proportion 
of this risk. There are only three case reports published for needle tract implantation 
of a thymoma reported in the chest wall after biopsy [26–28]. To abstain from a needle 
biopsy in order to avoid the risk of pleural seeding therefore seems unfounded [29].
In the case of potentially resectable or unresectable disease or when another 
diagnosis, such as lymphoma, is strongly suspected, tissue diagnosis is necessary. 
Biopsy should avoid a transpleural approach to prevent tumor seeding in the pleural 
space [21, 30]. Note that differentiation between lymphoma and thymoma can be 
difficult when a fine needle aspiration is done, so core needle biopsy or surgical 
biopsies are preferred [31].
5. Staging
There are several different staging systems for thymoma and thymic carcinoma, 
but the Masaoka-Koga staging system [32] and the American Joint Committee on 
Cancer (AJCC) the eighth edition of the TNM prognostic staging system [33] are 
the most commonly used.
Both staging systems are based on the extent of the primary tumor, invasion of 
adjacent structures and dissemination. In contrast to other thoracic cancers, both 
lymph node and distant metastases are considered stage IV disease. The Masaoka-
Koga staging system (Table 2) is a surgical-pathological system that can only be 
definitely ascertained after surgery is performed. Historically this has been the most 
widely used staging system, so most data supporting treatment options is based on 
patients staged according to the Masaoka-Koga system.
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Masaoka-
Koga stage
Diagnostic criteria
Stage I Macroscopically and microscopically completely
encapsulated
Stage II a. Microscopic transcapsular invasion
b. Macroscopic invasion into surrounding fatty tissue or grossly adherent to but not through 
mediastinal pleura or pericardium
Stage III Macroscopic invasion into neighboring organs (i.e., pericardium, great vessels, lung)
a. Without invasion in the great vessels
b. With invasion in great vessels
Stage IV a. Pleural or pericardial dissemination
b. Lymphogenous or hematogenous metastases
Table 2. 
Masaoka-Koga staging system.
TNM staging AJCC eighth edition
Primary tumor (T)
TX Primary tumor cannot be assessed
T0 No evidence of primary tumor
T1 Tumor encapsulated or extending into the mediastinal fat may involve the mediastinal pleura
T1a Tumor with no mediastinal pleural involvement
T1b tumor with direct invasion of mediastinal pleura
T2 Tumor with direct invasion of the pericardium (either partial or full thickness)
T3 Tumor with direct invasion into any of the following: lung, brachiocephalic vein, superior 
vena cava, phrenic nerve, chest wall, or extrapericardial pulmonary artery or veins
T4 Tumor with invasion into any of the following: aorta, arch vessels, intrapericardial 
pulmonary artery, myocardium, or trachea esophagus
Regional lymph nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastases in anterior (perithymic) lymph nodes
N2 Metastases in deep intrathoracic or cervical lymph nodes
Distant metastases (M)
M0 No pleural, pericardial, or distant metastases
M1 Pleural, pericardial, or distant metastases
M1a separate pleural or pericardial nodules
M1b pulmonary intraparenchymal nodule or distant organ metastases
Prognostic stage groups
T N M
Stage I T1a,b N0 M0
Stage II T2 N0 M0
Stage IIIa T3 N0 M0
Stage IIIb T4 N0 M0
Stage IVa Any T N1
N0–N1
M0
M1a
Stage IVb Any T N2
Any N
M0–M1a
M1b
Table 3. 
TNM staging AJCC eighth edition.
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In 2018, the AJCC published the eighth edition of the TNM staging system (Table 3). 
They incorporated a proposal from the International Association for the Study of Lung 
Cancer (IASLC) and the International Thymic Malignancy Interest Group (ITMIG) for 
the staging of thymoma and thymic carcinoma based on the anatomical extend of the 
tumor combined with prognostic factor. Survival data of 10,808 patients was used [33]. 
Because of this larger dataset, the addition of nodal metastasis and a better correlation 
with prognosis, we would advise the AJCC TNM staging system.
6. Management
There are no phase III randomized, clinical trials on the treatment of thymoma 
and thymic carcinoma. Although they are two different entities, the general manage-
ment per stage is almost the same. Surgery aimed at complete resection is the corner-
stone of thymoma and thymic carcinoma management and should always be pursued.
All patients should be managed by a multidisciplinary team with experience in the 
management of thymoma and thymic carcinoma. The choice of treatment depends 
on resectability, stage, and whether or not myasthenia gravis is present. In all stages of 
thymoma and thymic carcinoma, resectability should be considered. When deemed 
possible in stages IIIb and IVa, surgery is part of a multimodality approach [25, 34–37].
An example of management according to stage could be as shown in Table 4. 
One should realize though that there is no advise based on phase III randomized 
controlled trails available and every case should be considered individually and 
there are different options, as discussed below.
6.1 Treatment thymoma
6.1.1 Resectable disease
Once complete resection of a thymoma is deemed possible, complete resection 
of the thymus, the tumor, and the invaded structures (including resection of the 
lung parenchyma or pericardium and vena cava reconstruction if necessary) is 
Treatment thymoma and thymic carcinoma according to stage
AJCC TMN 
stage
Thymoma Thymic carcinoma
Stage I Complete resection Complete resection
Stage II Complete resection
Consider PORT in WHO type B2/3
Complete resection and PORT
Stage III Resectable or potentially resectable disease:
Multimodality approach
Consider neoadjuvant chemotherapy in IIIA 
tumors. Neoadjuvant chemotherapy in IIIb tumors
Complete resection or, when not feasible during 
surgery, maximum debulking
PORT
Unresectable disease
Chemoradiation
Resectable or potentially resectable disease:
Multimodality approach
Consider neoadjuvant chemotherapy in IIIA 
tumors. Neoadjuvant chemotherapy in IIIb 
tumors
Complete resection or, when not feasible 
during surgery, maximum debulking
PORT
Unresectable disease
Chemoradiation
Stage IV IVA same as stage III
IVB chemotherapy or individual approach
IVA same as stage III
IVB chemotherapy
Table 4. 
Treatment thymoma and thymic carcinoma according to stage.
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recommended [21, 25, 34, 36]. Preoperative evaluation for myasthenia gravis is 
advised. If this is diagnosed, treatment is essential, as myasthenia gravis can cause 
a postoperative myasthenic crisis or respiratory failure [38]. Thymoma Masaoka-
Koga stages I and II have a 5-year survival rate of 100% after surgery [1].
In the case of an incomplete resection, postoperative radiotherapy (PORT), 
either on the primary tumor or on isolated metastasis, is recommended to reduce 
the risk of recurrence [35, 39]. In the past PORT was considered standard treatment 
for stage II completely resected tumors [7, 40]. Nowadays PORT in completely 
resected stages I and II WHO type A, AB, and B1 thymoma is not considered useful 
[10, 41–43]. Because of a high recurrence rate (even after R0 resection)  PORT is 
advised for the higher stages and for WHO-type B2/3 thymoma and thymic carci-
noma [21, 44], although the data are somewhat conflicting in this [7].
6.1.2 Potentially resectable disease
More extensive thymomas can be initially irresectable but potentially resectable 
after neoadjuvant treatment. A multimodality approach containing neoadjuvant 
chemotherapy with or without postoperative radiotherapy should be used, depend-
ing on WHO type and resection margins [21, 35, 45–47].
Potential advantages of neoadjuvant chemotherapy are tumor downstaging and 
increasing the likelihood of complete resection. However, because the available data 
on chemotherapy in thymoma is based on small, phase II studies, there is no opti-
mal chemotherapeutic regime established [21]. Potential disadvantages could be 
complications due to chemotherapy and longer operating time [48]. There is even 
some recent data suggesting that there is no overall survival benefit to be expected 
from neoadjuvant chemotherapy before surgery [48–50]. In the cases of extensive 
pleural disease, several institutions have reported small series of extrapleural pneu-
monectomy for stage IVA disease with excellent outcomes and low morbidity [51].
There are no RCT’s available to settle this matter. For now, it is recommended 
to use neoadjuvant chemotherapy to downstage unresectable thymic malignancies 
before surgery [21]. Obviously, reevaluation after neoadjuvant therapy to determine 
whether or not the tumor responded sufficiently is mandatory. There is evidence 
supporting maximum debulking, combined with PORT and/or adjuvant chemo-
therapy, to benefit survival from a thymoma which turns out to be unresectable 
during surgery. This is, however, based on retrospective data, so selection bias could 
cloud this positive outcome [3, 52].
6.1.3 Unresectable disease
In the case of unresectable disease or the patients is inoperable due to condition 
or comorbidity, the possibility of radiation therapy should be assessed. If radiation is 
feasible, concurrent chemoradiation is advised. If radiation is not possible due to a too 
large field, palliative chemotherapy is recommended. But even in that setting, long-
term disease control and survival can be sometimes pursued, and even a combination 
of radiation on the primary tumor combined with resection of metastasis could be 
considered [21].
Chemotherapy is the primary modality in systemic management of unresect-
able thymoma. Thymomas are known to be sensitive to chemotherapy, possible 
due to a “lymphocytic effect” of cytotoxic agents. Due to the rarity of the disease 
and surgery with or without PORT being the cornerstone of treatment, there are 
no randomized controlled trails available to select a preferred regime. Platinum-
based combinations are standard of care, the most popular regimes being cisplatin 
with anthracycline and/or etoposide. The response rate range of these regimens is 
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between 25 and 100% [53]. The preferred regime by the NCCN is cisplatin/doxoru-
bicin/cyclophosphamide [21, 54].
Stereotactic radiotherapy (SBRT) may be appropriate for limited focal metasta-
sis; conventional fractionation is appropriate for larger metastasis [21].
Response rates for second-line therapy range from 15 to 39% [55]. Pemetrexed 
and paclitaxel are considered the most efficacious in second-line treatment of 
thymic malignancies, although this is based on small phase II studies and expert 
opinion [21, 56, 57].
Checkpoint inhibitors. Programmed death ligand 1 (PD-L1) expression is high 
(82%) in thymoma, especially in WHO type B thymoma [58]. Even so, based on 
a phase II study on pembrolizumab (a humanized IgG4 antibody to PD-L1) in 33 
thymic epithelial tumors (including 7 thymomas), immunotherapy is not recom-
mended in thymoma. This is because of the high grade of immune-related events 
that was shown in seven thymoma patients during this study; 71% had grade 3 or 
higher immune-related adverse events (including myocarditis) [59]. Avelumab is 
a fully human IgG1 anti-PD-L1 antibody that showed less adverse events (38%) in 
a phase I trial (n = 7). However, it is currently under clinical development, and no 
phase II data is available [60].
The high rate of immune-related side effect was expected; the physiological role 
of the thymus is to induce tolerance to self-antigens and deletion of autoimmune 
T cells. In the normal thymus, PD-1/PL-D1 expression regulates this self-tolerant 
T-cell repertoire. It is thought that disruption of the PD-1/PDL-1 system could lead 
to significant alteration of the T-cell population and therefore cause autoimmune-
related adverse events in the case of checkpoint inhibition [61].
Targeted therapies. Although there is high epidermal growth factor receptor 
(EGFR) expression in immunohistochemical staining of thymic epithelial tumors 
(71% for thymoma and 53% for thymic carcinoma), there is no correlation between 
the EGFR status and EGFR mutations. Experience with targeted therapies in thy-
moma is very limited and based on a small number of heterogenic phase II studies, 
but as for now this shows that there is no place for EGFR inhibitors in the treatment 
of thymoma and thymic carcinoma [7]. KIT-inhibition (inhibition of a trans-
membrane type III tyrosine kinase receptor) may show some promises in thymic 
carcinomas, but as thymomas do not show c-KIT expression [62], KIT-inhibition is 
not effective. There is some phase II experience in insulin-like growth factor (IGFR) 
inhibitors in thymoma patients that have shown some promising results [63]. 
Octreotide (a somatostatin analog) plus prednisolone may be useful in patients who 
have a positive octreotide scan [64].
6.1.4 Recurrent disease
The recurrence rate of thymoma after complete resection is 10–30%, and this 
can occur many years after initial treatment. Surgical resection of recurrent disease 
can be associated with long-term survival and should be considered for patients 
with recurrent thymoma. In pleural “drop” lesions, repeated resection is considered 
safe [50, 65].
6.2 Treatment thymic carcinoma
Similar to thymoma, surgery aimed at complete resection is the cornerstone of 
thymic carcinoma treatment, and the principles of first-line treatment in resectable 
disease are more or less the same. Five-year survival rate of 100% is reported for 
completely resected stage I disease going down to 17% in stage IVb disease [66]. 
Patients with a thymic carcinoma have a high risk of recurrent disease. Therefore, 
Thymus
10
some centers offer PORT (with or without chemotherapy) regardless of stage and 
resection margins [3, 21]. The available data is yet again limited, and there are 
indications that adjuvant therapy is not beneficial in R0-resected stage I thymic 
carcinoma [21, 42, 67].
Chemotherapy. Thymic carcinomas respond less to chemotherapy than thymo-
mas. Carboplatin/paclitaxel has the highest response rate in patients with thymic 
carcinoma, but even so this is only 22–36% [21, 55]. Response rates for second-line 
chemotherapy in thymic carcinoma are even worse (4–12%) [55].
Checkpoint inhibitors. Second-line treatment with pembrolizumab showed 
promising results in a phase II trial containing 40 patients with thymic carci-
noma. There was an ORR of 22.5%, and the median duration of response was 
22 months. While less in thymomas, there was still a high rate of immune-related 
adverse events (15%), including two cases of severe myocarditis [59]. A recently 
published study on nivolumab in thymic carcinoma patients showed no objective 
response in 15 patients, although 5 patients showed stable disease for more than 
24 weeks [68].
Targeted therapies. The same as in thymoma, experience with targeted thera-
pies in thymoma is very limited and based on small phase II studies and individual 
case reports. Sunitinib may be beneficial for patients with a c-KIT mutation, 
although the mutation rate is rare <10% [10, 69]. IGFR inhibition and octreotide 
did not show any activity in thymic carcinoma, in contrast to thymomas [63, 64].
6.3 Follow-up
After primary resection, expert opinion on follow-up consists of a CT scan every 
6 months for 2 years, then annually for 5 years for thymic carcinoma and annually 
for 10 years for thymomas [21], although an exceptional case of late recurrence has 
been reported [70].
7. Conclusion
Thymomas and thymic carcinomas are rare mediastinal tumors, and although 
the course of a thymoma can be indolent, they can indeed be locally invasive and 
metastasize. Thymic carcinomas more often are disseminated at presentation. 
Therefore, both are considered malignant. Forty to fifty percent of thymomas 
are related to autoimmune paraneoplastic syndromes, the most common being 
myasthenia gravis. Resection of the thymus can also act as treatment for the para-
neoplastic syndrome. However, thymic treatment does not always resolve those 
paraneoplastic syndromes.
Because of the improved representation of the N-stage and correlation to 
prognosis, rather than surgical resectability, we recommend the AJCC eighth TMN 
classification.
There is no phase III data available on the management of thymic epithelial 
tumors. Surgery is considered the cornerstone of thymoma and thymic carcinoma 
management in resectable disease and even in recurrent disease. Neoadjuvant treat-
ment and PORT should be considered according to stage.
In metastatic disease chemotherapy containing an anthracycline is advised. For 
recurrent metastatic disease sunitinib and octreotide, among other things, could be 
considered. A special note on checkpoint inhibitors should be made. Although they 
do show promising results in thymic carcinoma, the rate of immune-related adverse 
events is too high to consider this a valuable option for the treatment of thymoma 
right now.
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The lack of phase III level evidence due to the rarity of the disease calls for 
collaboration in research to improve the quality and impact of thymic malignancy 
treatment. Such efforts are currently underway, and hopefully this will lead to bet-
ter and more treatment options in the future.
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